Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 study of nedosiran in primary hyperoxaluria
NL-OMON59674Phase 3Active, not recruiting
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Aug 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of nedosiran in Primary hyperoxaluria (PH), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Annual rate of decline in eGFR in PH1. Started Aug 2019; status: active, not recruiting.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NL-OMON59674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59674.